|
|
Volumn 78, Issue 12 A, 1996, Pages 2-7
|
|
Molecular biology of plasminogen activators: what are the clinical implications of drug design?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PLASMINOGEN ACTIVATOR;
RECOMBINANT PROTEIN;
RETEPLASE;
STREPTOKINASE;
TISSUE PLASMINOGEN ACTIVATOR;
ANIMAL;
BLEEDING;
BRAIN HEMORRHAGE;
CHEMICALLY INDUCED DISORDER;
CHEMISTRY;
COMPARATIVE STUDY;
DISEASE MODEL;
DRUG ADMINISTRATION;
DRUG DESIGN;
FIBRINOLYTIC THERAPY;
GENETICS;
HALF LIFE TIME;
HEART INFARCTION;
HEART MUSCLE REPERFUSION;
HUMAN;
MOLECULAR BIOLOGY;
POINT MUTATION;
REVIEW;
RISK FACTOR;
SURVIVAL RATE;
ANIMALS;
CEREBRAL HEMORRHAGE;
DISEASE MODELS, ANIMAL;
DRUG ADMINISTRATION SCHEDULE;
DRUG DESIGN;
HALF-LIFE;
HEMORRHAGE;
HUMANS;
MOLECULAR BIOLOGY;
MYOCARDIAL INFARCTION;
MYOCARDIAL REPERFUSION;
PLASMINOGEN ACTIVATORS;
POINT MUTATION;
RECOMBINANT PROTEINS;
RISK FACTORS;
STREPTOKINASE;
SURVIVAL RATE;
THROMBOLYTIC THERAPY;
TISSUE PLASMINOGEN ACTIVATOR;
|
|
EID: 0030593897
PISSN: 00029149
EISSN: None
Source Type: Journal
DOI: 10.1016/S0002-9149(96)00736-9 Document Type: Article |
|
Times cited : (60)
|
|
References (38)
|
